Table 5.
Demographic and anamnestic determinants of COVID-19 vaccine booster acceptance among polish healthcare professionals and students responding to COVID-19 VBH survey, December 2021–January 2022 (n = 443).
| Variable | Outcome | Rejection (n = 78) | Sig. | Hesitancy (n = 35) | Sig. | Acceptance (n = 330) | Sig. |
|---|---|---|---|---|---|---|---|
| Gender | Female* | 57 (16.9%) | Reference | 28 (8.3%) | Reference | 253 (74.9%) | Reference |
| Male | 20 (19.8%) | 0.496 | 6 (5.9%) | 0.442 | 75 (74.3%) | 0.904 | |
| Diverse-gender | 1 (25%) | 0.670 | 1 (25%) | 0.265 | 2 (50%) | 0.279 | |
| Pregnancy* | Yes | 1 (14.3%) | 1.000 | 1 (14.3%) | 0.457 | 5 (71.4%) | 1.000 |
| No | 56 (16.9%) | 27 (8.2%) | 248 (74.9%) | ||||
| Age group | >30 years-old | 33 (18.6%) | 0.579 | 16 (9%) | 0.476 | 128 (72.3%) | 0.354 |
| ≤ 30 years-old | 44 (16.6%) | 19 (7.2%) | 202 (76.2%) | ||||
| Prior COVID-19 infection | Yes† | 34 (24.1%) | 0.014 | 14 (9.9%) | 0.280 | 93 (66%) | 0.005 |
| No | 44 (14.6%) | 21 (7%) | 237 (78.5%) | ||||
| Onset† | Before 1st dose | 29 (28.2%) | Reference | 8 (7.8%) | Reference | 66 (64.1%) | Reference |
| Between 1/2 doses | 2 (33.3%) | 0.785 | 0 (0%) | 0.993 | 4 (66.7%) | 0.898 | |
| After 2nd dose | 3 (9.4%) | 0.039 | 6 (18.8%) | 0.084 | 23 (71.9%) | 0.418 | |
| Severity† | Asymptomatic | 2 (50%) | Reference | 1 (25%) | Reference | 1 (25%) | Reference |
| Mild | 19 (20.4%) | 0.188 | 8 (8.6%) | 0.297 | 66 (71%) | 0.091 | |
| Moderate | 13 (31.7%) | 0.467 | 5 (12.2%) | 0.483 | 23 (56.1%) | 0.262 | |
| Severe | 0 (0%) | 0.990 | 0 (0%) | 0.991 | 3 (100%) | 0.990 | |
| COVID-19 vaccination | Yes ‡ | 52 (12.5%) | <0.001 | 34 (8.2%) | 0.714 | 329 (79.3%) | <0.001 |
| No | 26 (92.9%) | 1 (3.6%) | 1 (3.6%) | ||||
| Vaccine type‡ | Pfizer-BioNTech | 38 (11.7%) | 0.327 | 27 (8.3%) | 0.871 | 260 (80%) | 0.490 |
| Moderna | 1 (5%) | 0.491 | 2 (10%) | 0.674 | 17 (85%) | 0.777 | |
| AstraZeneca-Oxford | 5 (9.3%) | 0.436 | 3 (5.6%) | 0.599 | 46 (85.2%) | 0.251 | |
| Janssen | 8 (50%) | <0.001 | 2 (12.5%) | 0.631 | 6 (37.5%) | <0.001 | |
| Number of doses‡ | One dose | 8 (44.4%) | <0.001 | 5 (27.8%) | 0.011 | 5 (27.8%) | <0.001 |
| Two doses | 19 (21.1%) | 0.005 | 17 (18.9%) | <0.001 | 54 (60%) | <0.001 | |
| Three doses | 25 (8.1%) | <0.001 | 12 (3.9%) | <0.001 | 270 (87.9%) | <0.001 | |
| Hospital admission‡ | Yes | 5 (35.7%) | 0.021 | 2 (14.3%) | 0.321 | 7 (50%) | 0.013 |
| No | 47 (11.7%) | 32 (8%) | 322 (80.3%) | ||||
| Medical care‡ | Yes | 6 (33.3%) | 0.016 | 3 (16.7%) | 0.175 | 9 (50%) | 0.005 |
| No | 46 (11.6%) | 31 (7.8%) | 320 (80.6%) |
Logistic regression, Chi-squared test (χ2) and Fisher's exact test had been used with a significance level (Sig.) <0.05.
*
Refers to female participants.
†
Refers to the previously infected participants.
‡
Refers to the previously vaccinated participants.
Bold values - statistically significant with p <0.05.